Cellanyx, LLC

Cellanyx is a growth stage emerging biotech advancing proprietary phenotypic (appearance and dynamics) biomarker tests based on Machine Vision and AI-driven analysis of live single tumor cells to improve risk-stratification and shared clinical decision-making for solid tumors. LDT evaluated in nearly 500 patient samples across prostate, breast, kidney, bladder and lung cancers.